Carl Icahn disclosed in a regulatory filing no position in Bausch Health (BHC). Icahn has sold his firm’s entire position in Bausch Health.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Durect, Bausch Health merger expected to close in Q3
- Bausch + Lomb price target raised to $13 from $11 at BofA
- Bausch Health reports Q2 GAAP EPS 40c vs. 3c last year
- Bausch Health to acquire Durect for $1.75 per share in cash upfront
- Bausch Health to acquire Durect for $1.75 per share in an all-cash transaction